NASDAQ:CALC - Nasdaq - US38942Q2021 - Common Stock - Currency: USD
Overall CALC gets a fundamental rating of 1 out of 10. We evaluated CALC against 195 industry peers in the Pharmaceuticals industry. CALC may be in some trouble as it scores bad on both profitability and health. CALC does not seem to be growing, but still is valued expensively.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -74.45% | ||
ROE | -173.33% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.79 | ||
Debt/FCF | N/A | ||
Altman-Z | -10.36 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 5.66 | ||
Quick Ratio | 5.66 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:CALC (6/9/2025, 1:35:14 PM)
1.79
+0.05 (+2.87%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | N/A | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 2.3 | ||
P/tB | 2.3 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -74.45% | ||
ROE | -173.33% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.79 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | N/A | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 5.66 | ||
Quick Ratio | 5.66 | ||
Altman-Z | -10.36 |